ReNeuron Group plc Notice of Results (7909Z)
May 18 2023 - 2:00AM
UK Regulatory
TIDMRENE
RNS Number : 7909Z
ReNeuron Group plc
18 May 2023
ReNeuron Group plc
("ReNeuron" or the "Company")
Notice of Results
Investor presentation
ReNeuron Group plc (AIM: RENE) , a UK-based leader in stem cell
derived exosome technologies , will announce its preliminary
results for the year ended 31 March 2023 on Thursday 25 May
2023.
Investor Briefing
Management will also be hosting a live online presentation
relating to the preliminary results via the Investor Meet Company
platform at 9:30am BST on Thursday 25 May 2023. The presentation is
open to all existing and potential shareholders.
Investors can sign up to Investor Meet Company for free and
register for the presentation here:
https://www.investormeetcompany.com/reneuron-group-plc/register-investor
Investors who already follow ReNeuron on the Investor Meet
Company platform will automatically be invited.
Questions can be submitted pre-event via your IMC dashboard or
in real time during the presentation, via the "Ask a Question"
function. Whilst the Company may not be in a position to answer
every question it receives, it will address the most prominent
within the confines of information already disclosed to the market
through regulatory notifications. A recording of the presentation,
a PDF of the slides used, and responses to the Q&A session will
be available on the Investor Meet Company platform afterwards.
ENDS
Enquiries:
ReNeuron www.reneuron.com/investors
Iain Ross, Executive Chairman Via Walbrook PR
John Hawkins, Chief Financial Officer
Allenby Capital Limited (Nominated
Adviser and Broker) +44 (0)20 3328 5656
James Reeve/George Payne/Dan Dearden-Williams
(Corporate Finance)
Stefano Aquilino (Sales & Corporate
Broking)
Walbrook PR (Media & Investor Relations) +44 (0)20 7933 8780
Paul McManus / Alice Woodings or reneuron@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7407
804 654
About ReNeuron
ReNeuron has developed a proprietary stem cell-derived,
exosome-based, drug delivery platform with customisable cellular
targeting capabilities for the delivery of complex drug
modalities.
Through the generation of several unique and scalable exosome
producer cell lines, our CustomEX(TM) platform can be optimised for
specific tissues targets and payloads leading to improvements in
therapeutic outcome and a reduction in off-target effects. ReNeuron
offers a delivery mechanism for a variety of payloads such as
siRNA, mRNA, proteins, small molecules and genes. Through its
conditionally immortalised induced pluripotent stem cell (iPSC)
platform, the Company can make allogeneic tissue cells of choice
and has the potential to produce exosomes with tissue specific
targeting ability.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. For further information visit www.reneuron.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORQDLFFXELEBBE
(END) Dow Jones Newswires
May 18, 2023 02:00 ET (06:00 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From Dec 2024 to Jan 2025
Reneuron (LSE:RENE)
Historical Stock Chart
From Jan 2024 to Jan 2025
